Evidence map›Paper›PMID 38442159›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

Engineered mRNA-ribosome fusions for facile biosynthesis of selenoproteins.

Anna Thaenert, Anastasia Sevostyanova, Christina Z Chung, Oscar Vargas-Rodriguez, Sergey V Melnikov, Dieter Söll

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Anna Thaenert *Department of Molecular Biophysics & Biochemistry, Yale University, New Haven, CT 06511.
Anastasia Sevostyanova *Department of Molecular Biophysics & Biochemistry, Yale University, New Haven, CT 06511.
Christina Z Chung *Department of Molecular Biophysics & Biochemistry, Yale University, New Haven, CT 06511.
Oscar Vargas-Rodriguez *Department of Molecular Biophysics & Biochemistry, Yale University, New Haven, CT 06511.
Sergey V MelnikovBiosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, United Kingdom.
Dieter SöllDepartment of Molecular Biophysics & Biochemistry, Yale University, New Haven, CT 06511.ORCID 0000-0002-3077-8986
Yale University · USNewcastle University · GB

Funding

Studies of Transfer RNAR35GM122560 · NIGMS · YALE UNIVERSITY · PI SOLL, DIETER · 2017 to 2022
$5.6M
NIGMS NIH HHS R35 GM122560
6 · The paper itself

Abstract

Ribosomes are often used in synthetic biology as a tool to produce desired proteins with enhanced properties or entirely new functions. However, repurposing ribosomes for producing designer proteins is challenging due to the limited number of engineering solutions available to alter the natural activity of these enzymes. In this study, we advance ribosome engineering by describing a novel strategy based on functional fusions of ribosomal RNA (rRNA) with messenger RNA (mRNA). Specifically, we create an mRNA-ribosome fusion called RiboU, where the 16S rRNA is covalently attached to selenocysteine insertion sequence (SECIS), a regulatory RNA element found in mRNAs encoding selenoproteins. When SECIS sequences are present in natural mRNAs, they instruct ribosomes to decode UGA codons as selenocysteine (Sec, U) codons instead of interpreting them as stop codons. This enables ribosomes to insert Sec into the growing polypeptide chain at the appropriate site. Our work demonstrates that the SECIS sequence maintains its functionality even when inserted into the ribosome structure. As a result, the engineered ribosomes RiboU interpret UAG codons as Sec codons, allowing easy and site-specific insertion of Sec in a protein of interest with no further modification to the natural machinery of protein synthesis. To validate this approach, we use RiboU ribosomes to produce three functional target selenoproteins in

Indexed as

MagnoliopsidaSelenocysteineCodon, TerminatorEscherichia coliRibosomesRNA, MessengerRNA, Ribosomal, 16SSelenoproteinsCodon, TerminatorRNA, MessengerRNA, Ribosomal, 16SSelenocysteineSelenoproteinsribosome engineeringSECISselenocysteinetranslationtRNA

Identifiers

PMID38442159
PMCPMC10945757
OpenAlexW4392451764

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.